<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01401075</url>
  </required_header>
  <id_info>
    <org_study_id>AB-AVQ20-1.0</org_study_id>
    <nct_id>NCT01401075</nct_id>
  </id_info>
  <brief_title>RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients</brief_title>
  <official_title>Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abnoba Gmbh</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abnoba Gmbh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of safety and efficacy of a standardized mistletoe extract (abnobaVISCUMÂ® Quercus,
      aVQ) in patients with gastric cancer receiving oral chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24 weeks</time_frame>
    <description>EORTC Quality of Life Questionnaires:
QLQ-C30
QLQ-STO22</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunomodulation</measure>
    <time_frame>24 weeks</time_frame>
    <description>cytokine levels (TNF-alpha and interleukin-2)
lymphocyte subsets (CD 16+/CD56+ and CD 19+)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>24 weeks</time_frame>
    <description>differential blood count
liver functions tests
adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>doxifluridine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral chemotherapy with the 5-FU prodrug doxifluridine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>doxifluridine + mistletoe extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral chemotherapy with the 5-FU prodrug doxifluridine + mistletoe extract as subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mistletoe extract</intervention_name>
    <description>subcutaneous injections thrice weekly with 1 ml in 4 increasing doses</description>
    <arm_group_label>doxifluridine + mistletoe extract</arm_group_label>
    <other_name>abnobaVISCUM Quercus 0.02 mg</other_name>
    <other_name>abnobaVISCUM Quercus 0.2 mg</other_name>
    <other_name>abnobaVISCUM Quercus 2 mg</other_name>
    <other_name>abnobaVISCUM Quercus 20 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxifluridine</intervention_name>
    <description>600 - 900 mg per day orally, depending on weight and status of the patient</description>
    <arm_group_label>doxifluridine</arm_group_label>
    <arm_group_label>doxifluridine + mistletoe extract</arm_group_label>
    <other_name>Didox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  postoperative UICC stage Ib/II gastric carcinoma

          -  indication for oral chemotherapy with doxifluridine

          -  ECOG performance status 0 or 1

          -  normal liver and kidney function

        Exclusion Criteria:

          -  inability to answer the QoL scales

          -  concomitant therapy with steroids or biological response modifiers

          -  individual hypersensitivity to mistletoe preparations

          -  pregnancy or lactating

          -  participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung-Sik Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASAN Medical Center, Seoul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Kim KC, Yook JH, Eisenbraun J, Kim BS, Huber R. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. BMC Complement Altern Med. 2012 Oct 3;12:172. doi: 10.1186/1472-6882-12-172.</citation>
    <PMID>23033982</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2011</study_first_submitted>
  <study_first_submitted_qc>July 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2011</study_first_posted>
  <last_update_submitted>November 6, 2012</last_update_submitted>
  <last_update_submitted_qc>November 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of Life</keyword>
  <keyword>QoL</keyword>
  <keyword>EORTC QLQ-C30</keyword>
  <keyword>EORTC QLQ-STO22</keyword>
  <keyword>5-FU</keyword>
  <keyword>Viscum album</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxifluridine</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
    <mesh_term>Viscum album peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

